Drug intelligence / Profile preview

vero cell-derived trivalent influenza vaccine (modified)

Development stage
Unknown
Lead developer
Takeda
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

The **vero cell-derived trivalent influenza vaccine (modified)** is an inactivated influenza vaccine produced using the Vero cell line (derived from African green monkey kidney cells), instead of the traditional embryonated chicken eggs[1][2][3][6][8]. This vaccine contains inactivated viral antigens from three influenza strains: typically two influenza A subtypes (H1N1 and H3N2) and one influenza B lineage (B/Victoria), as recommended for recent influenza seasons[5][7][9]. Vero cell-based production offers advantages including scalability, faster production, and suitability for those with egg allergies[2][3][6][8]. The “modified” formulation refers to changes in composition or production, such as strain selection or cell culture optimization[5][7]. The vaccine works by stimulating the immune system to produce antibodies against the included strains, thereby providing prophylactic protection against influenza infection[3]. Clinically, Vero cell-derived trivalent influenza vaccines have demonstrated efficacy (~78.5% for matched strains) and a favorable safety profile[3].

Brand names
Preflucel
Other names
vero cell-derived trivalent influenza vaccinevero cell trivalent influenza vaccine
02

Targets

HA (Hemagglutinin)Neuraminidase

Beyond the preview

Go deeper on vero cell-derived trivalent influenza vaccine (modified).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on vero cell-derived trivalent influenza vaccine (modified).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call